According to a new report by Expert Market Research, the RNA Therapeutics Market was valued at USD 15.28 Billion in 2025 and is projected to reach USD 26.35 Billion by 2035, expanding at a CAGR of 5.6% during 2026–2035.

The RNA Therapeutics Market is witnessing strong momentum supported by advancements in mRNA, RNA interference, and antisense technologies, with growing investments from leading biotechnology firms including Moderna, Inc. and BioNTech SE. The continues to evolve rapidly as Expert Market Research highlights increasing clinical trials, regulatory approvals, and expanding therapeutic applications across infectious and genetic diseases.

Key growth drivers include rising prevalence of genetic disorders, increasing demand for advanced infectious disease treatments, and rapid innovation in RNA-based vaccine platforms. Expert Market Research also emphasizes the role of government funding and public-private partnerships in accelerating development pipelines.

Access a Complimentary Sample Report with Full Table of Contents

Market outlook remains highly positive as biotech firms expand their RNA portfolios and strengthen global collaborations. Expert Market Research notes that ongoing technological breakthroughs in RNA delivery systems and sequencing technologies are expected to further enhance market penetration over the forecast period.

Market Overview

The RNA Therapeutics Market represents a rapidly advancing segment of modern biotechnology focused on developing RNA-based treatments for a wide range of diseases. Expert Market Research identifies this market as a critical driver of next-generation precision medicine, particularly in oncology, rare diseases, and infectious conditions. Increasing adoption of mRNA platforms and RNA interference technologies is reshaping therapeutic development strategies globally.

Market Size & Forecast: Expert Market Research Projections

The RNA Therapeutics Market was valued at USD 15.28 Billion in 2025 and is projected to grow steadily at a CAGR of 5.6% from 2026 to 2035. By the end of the forecast period, the market is expected to reach USD 26.35 Billion. Expert Market Research attributes this growth to strong pipeline expansion, rising demand for targeted therapies, and increasing investment in RNA-based drug development.

Macroeconomic & Industry Linkage Analysis

Macroeconomic factors such as rising healthcare expenditure, increased biotechnology funding, and expanding pharmaceutical R&D activities are significantly influencing the RNA therapeutics sector. Expert Market Research highlights that global healthcare transformation and digital biology integration are accelerating market expansion.

In addition, geopolitical disruptions and supply chain volatility have impacted raw material availability and production costs. However, sustained investment in domestic biomanufacturing capabilities is helping stabilize long-term growth prospects for the RNA therapeutics ecosystem.

Key Growth Drivers

• Rising Genetic Disorder Prevalence: Increasing incidence of hereditary diseases is boosting demand for RNA-based therapies.
• Technological Advancements: Continuous innovation in mRNA and RNAi platforms enhances treatment precision.
• Expanding Vaccine Development: RNA-based vaccines are transforming infectious disease prevention strategies.
• Strong R&D Investments: Biopharmaceutical companies are significantly increasing RNA-focused research funding.
• Regulatory Approvals: Faster approvals are encouraging commercialization of RNA therapeutics globally.

Market Trends

One of the key trends in the RNA Therapeutics Market is the rising adoption of mRNA-based platforms beyond infectious diseases into oncology and rare genetic disorders. Expert Market Research indicates that personalized medicine approaches are becoming increasingly integrated into RNA drug development pipelines.

Another notable trend is the expansion of strategic partnerships between biotechnology firms and pharmaceutical giants. These collaborations are accelerating clinical translation and improving global access to advanced RNA-based treatments.

Market Challenges & Risk Factors

High development costs and complex manufacturing processes remain major challenges for RNA therapeutics. Expert Market Research notes that ensuring stability and efficient delivery of RNA molecules continues to be a technical barrier.

Additionally, stringent regulatory requirements and cold-chain logistics constraints pose operational risks, particularly for large-scale global distribution of RNA-based drugs.

Market Opportunities & White Space Areas

Emerging opportunities include expansion into rare disease treatment segments and development of next-generation RNA delivery systems. Expert Market Research highlights that lipid nanoparticle technologies are unlocking new possibilities in targeted therapy.

Furthermore, increasing demand in emerging economies presents untapped potential for market players focusing on affordable RNA therapeutic solutions.

Value Chain & Supply Chain Analysis

The RNA therapeutics value chain includes research and discovery, preclinical development, clinical trials, manufacturing, and commercialization. Expert Market Research emphasizes that advancements in synthetic biology and automated production are improving efficiency across the supply chain, reducing time-to-market for RNA-based drugs.

Market Segmentation Analysis

Product

• Vaccines
• Drugs

Type

• mRNA Therapeutics
• RNA Interference (RNAi) Therapeutics
• Antisense Oligonucleotide (ASO) Therapeutics
• Others

Indication

• Infective Diseases
• Rare Genetic Diseases/Hereditary Diseases
• Others

End User

• Hospitals & Clinics
• Research Center
• Others

Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Competitive Landscape

The RNA therapeutics industry is highly competitive, with leading players focusing on innovation and pipeline expansion. Expert Market Research identifies the following companies as key contributors:

• Moderna, Inc. (USA) - mRNA vaccine and therapeutic development
• BioNTech SE (Germany) - RNA-based immunotherapy solutions
• Alnylam Pharmaceuticals, Inc. (USA) - RNAi therapeutics leader
• Ionis Pharmaceuticals, Inc. (USA) - Antisense oligonucleotide therapies
• Arcturus Therapeutics Holdings Inc. (USA) - RNA technology platforms
• CureVac N.V. (Germany) - mRNA-based drug development
• Sarepta Therapeutics, Inc. (USA) - rare disease RNA therapies
• Wave Life Sciences Ltd. (Singapore) - precision RNA medicines
• Novo Nordisk A/S (Denmark) - metabolic and RNA research initiatives
• Sanofi S.A. (France) - diversified RNA therapeutic pipelines

Frequently Asked Questions (FAQs)

1. What is the current size of the RNA Therapeutics Market?
The market was valued at USD 15.28 Billion in 2025 according to Expert Market Research.

2. What is the projected CAGR of the RNA Therapeutics Market?
The market is expected to grow at a CAGR of 5.6% during 2026–2035 as per Expert Market Research.

3. Which region dominates the RNA Therapeutics Market?
North America currently dominates due to strong biotech infrastructure and R&D investment.

4. Who are the key players in the RNA Therapeutics Market?
Moderna, BioNTech, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Arcturus Therapeutics, CureVac, Sarepta Therapeutics, Wave Life Sciences, Novo Nordisk, and Sanofi are key players highlighted by Expert Market Research.

5. What are the major growth drivers of the RNA Therapeutics Market?
Rising genetic disease prevalence, technological advancements, and strong R&D investments are key drivers.

6. What are the key segments of the RNA Therapeutics Market?
The market is segmented by product, type, indication, end user, and region.

7. What challenges does the RNA Therapeutics Market face?
High costs, regulatory complexities, and cold-chain logistics remain major challenges.

8. What is the forecast value of the RNA Therapeutics Market by 2035?
The market is projected to reach USD 26.35 Billion by 2035 according to Expert Market Research.

"

About Us:

Expert Market Research is a global market intelligence and consulting platform by Claight delivering data-driven insights across commodities, chemicals, energy, and industrial markets. We design our research to support businesses, analysts, investors, and procurement teams in understanding price trends, supply-demand dynamics, competitive landscapes, gaining competitive intelligence, benchmarking best practices, and developing long-term market outlooks.

Our robust research methodologies, combined with validated primary and secondary data, ensure accuracy, consistency, and relevance. Our analysis is widely used not only for strategic planning, market-entry assessments, and sourcing decisions, but also for investment evaluation across international markets. Our strong emphasis on transparency, factual reporting, and regular data updates to reflect real-time market conditions always keeps you ahead of the curve.

Media Contact:

Company Name: Claight Corporation
Email: sales@expertmarketresearch.com
Toll Free Number: +1-415-325-5166 | +44-702-402-5790
Address: C-130 Sector 2 Noida, Uttar Pradesh 201301
Website: https://www.expertmarketresearch.com